Schrödinger Q1 revenue slips 2% to $58.6 million; ACV rises 12% to $28.4 million
Schrödinger reported first quarter 2026 results with total revenue of $58.6 million, down 2% from a year earlier, and a net loss of $60.0 million compared with $59.8 million. Annual contract value (ACV) grew 12% to $28.4 million, while the company kept its full-year 2026 guidance unchanged, including ACV of $218 million to $228 million.
Key points
- Total revenue was $58.6 million, down 2%. Software revenue fell 21% to $35.6 million as the company accelerates its shift to hosted licensing, while drug discovery revenue rose to $22.9 million from $10.2 million.
- ACV was $28.4 million, up 12%, and $201 million on a trailing four-quarter basis.
- Full-year 2026 guidance was maintained: ACV of $218 million to $228 million and drug discovery revenue of $55 million to $65 million.
- Cash, cash equivalents, restricted cash and marketable securities totaled $406 million at March 31, 2026.
The filing
Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.